Menu
Estimation of benefits, harms, and resource requirements to implement new
screening approaches
Summary
Regional (North, East, South and West) MISCAN models for prostate, gastric and lung cancer will be developed, based on data of one exemplary country per region. New elements in these data collections are smoking history patterns, the amount of opportunistic PSA testing and the prevalence of H. pylori. The prostate cancer model will be cross validated by the UMIT TIROL model. Next, the EU-TOPIA web-based tool with options will be extended to simulate these new cancers. We will assist other countries in collecting data required in the web tool, application of the web tool and interpretation of the model results.
This task will be led by EMC, Netherlands.
Subscribe to our newsletter to get news and updates.
Subscribe to our newsletter to get news and updates.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959
